Management of Patients with Advanced Prostate Cancer. Report from the 2024 Advanced Prostate Cancer Consensus Conference (APCCC)

Silke Gillessen; Fabio Turco; Ian D. Davis; Jason A. Efstathiou; Karim Fizazi; Nicholas D. James; Neal Shore; Eric Small; Matthew Smith; Christopher J. Sweeney; Bertrand Tombal; Thomas Zilli; Neeraj Agarwal; Emmanuel S. Antonarakis; Ana Aparicio; Andrew J. Armstrong; Diogo Assed Bastos; Gerhardt Attard; Karol Axcrona; Mouna Ayadi; Himisha Beltran; Anders Bjartell; Pierre Blanchard; Maria T. Bourlon; Alberto Briganti; Muhammad Bulbul; Consuelo Buttigliero; Orazio Caffo; Daniel Castellano; Elena Castro; Heather H. Cheng; Kim N. Chi; Caroline S. Clarke; Noel Clarke; Johann S. de Bono; Maria De Santis; Ignacio Duran; Eleni Efstathiou; Onyeanunam N. Ekeke; Tamer I.H. El Nahas; Louise Emmett; Stefano Fanti; Omolara A. Fatiregun; Felix Y. Feng; Peter C.C. Fong; Valerie Fonteyne; Nicola Fossati; Daniel J. George; Martin E. Gleave; Gwenaelle Gravis; Susan Halabi; Daniel Heinrich; Ken Herrmann; Michael S. Hofman; Thomas A. Hope; Lisa G. Horvath; Maha H.A. Hussain; Barbara Alicja Jereczek-Fossa; Robert J. Jones; Anthony M. Joshua; Ravindren Kanesvaran; Daniel Keizman; Raja B. Khauli; Gero Kramer; Stacy Loeb; Brandon A. Mahal; Fernando C. Maluf; Joaquin Mateo; David Matheson; Mika P. Matikainen; Ray McDermott; Rana R. McKay; Niven Mehra; Axel S. Merseburger; Alicia K. Morgans; Michael J. Morris; Hind Mrabti; Deborah Mukherji; Declan G. Murphy; Vedang Murthy; Shingai B.A. Mutambirwa; Paul L. Nguyen; William K. Oh; Piet Ost; Joe M. O'Sullivan; Anwar R. Padhani; Chris Parker; Darren M.C. Poon; Colin C. Pritchard; Danny M. Rabah; Dana Rathkopf; Robert E. Reiter; Raphaele Renard-Penna; Charles J. Ryan; Fred Saad; Juan Pablo Sade; Shahneen Sandhu; Oliver A. Sartor; Edward Schaeffer; Howard I. Scher; Nima Sharifi; Iwona A. Skoneczna; Howard R. Soule; Daniel E. Spratt; Sandy Srinivas; Cora N. Sternberg; Hiroyoshi Suzuki; Mary Ellen Taplin; Camilla Thellenberg-Karlsson; Derya Tilki; Levent N. Türkeri; Hiroji Uemura; Yüksel Ürün; Claire L. Vale; Neha Vapiwala; Jochen Walz; Kosj Yamoah; Dingwei Ye; Evan Y. Yu; Almudena Zapatero; Aurelius Omlin

doi:10.1016/j.eururo.2024.09.017

Management of Patients with Advanced Prostate Cancer. Report from the 2024 Advanced Prostate Cancer Consensus Conference (APCCC)

Silke Gillessen^*, Fabio Turco, Ian D. Davis, Jason A. Efstathiou, Karim Fizazi, Nicholas D. James, Neal Shore, Eric Small, Matthew Smith, Christopher J. Sweeney, Bertrand Tombal, Thomas Zilli, Neeraj Agarwal, Emmanuel S. Antonarakis, Ana Aparicio, Andrew J. Armstrong, Diogo Assed Bastos, Gerhardt Attard, Karol Axcrona, Mouna AyadiHimisha Beltran, Anders Bjartell, Pierre Blanchard, Maria T. Bourlon, Alberto Briganti, Muhammad Bulbul, Consuelo Buttigliero, Orazio Caffo, Daniel Castellano, Elena Castro, Heather H. Cheng, Kim N. Chi, Caroline S. Clarke, Noel Clarke, Johann S. de Bono, Maria De Santis, Ignacio Duran, Eleni Efstathiou, Onyeanunam N. Ekeke, Tamer I.H. El Nahas, Louise Emmett, Stefano Fanti, Omolara A. Fatiregun, Felix Y. Feng, Peter C.C. Fong, Valerie Fonteyne, Nicola Fossati, Daniel J. George, Martin E. Gleave, Gwenaelle Gravis, Susan Halabi, Daniel Heinrich, Ken Herrmann, Michael S. Hofman, Thomas A. Hope, Lisa G. Horvath, Maha H.A. Hussain, Barbara Alicja Jereczek-Fossa, Robert J. Jones, Anthony M. Joshua, Ravindren Kanesvaran, Daniel Keizman, Raja B. Khauli, Gero Kramer, Stacy Loeb, Brandon A. Mahal, Fernando C. Maluf, Joaquin Mateo, David Matheson, Mika P. Matikainen, Ray McDermott, Rana R. McKay, Niven Mehra, Axel S. Merseburger, Alicia K. Morgans, Michael J. Morris, Hind Mrabti, Deborah Mukherji, Declan G. Murphy, Vedang Murthy, Shingai B.A. Mutambirwa, Paul L. Nguyen, William K. Oh, Piet Ost, Joe M. O'Sullivan, Anwar R. Padhani, Chris Parker, Darren M.C. Poon, Colin C. Pritchard, Danny M. Rabah, Dana Rathkopf, Robert E. Reiter, Raphaele Renard-Penna, Charles J. Ryan, Fred Saad, Juan Pablo Sade, Shahneen Sandhu, Oliver A. Sartor, Edward Schaeffer, Howard I. Scher, Nima Sharifi, Iwona A. Skoneczna, Howard R. Soule, Daniel E. Spratt, Sandy Srinivas, Cora N. Sternberg, Hiroyoshi Suzuki, Mary Ellen Taplin, Camilla Thellenberg-Karlsson, Derya Tilki, Levent N. Türkeri, Hiroji Uemura, Yüksel Ürün, Claire L. Vale, Neha Vapiwala, Jochen Walz, Kosj Yamoah, Dingwei Ye, Evan Y. Yu, Almudena Zapatero, Aurelius Omlin

^*Corresponding author for this work

Research output: Contribution to journal › Article › peer-review

5 Scopus citations

Abstract

Background and objective: Innovations have improved outcomes in advanced prostate cancer (PC). Nonetheless, we continue to lack high-level evidence on a variety of topics that greatly impact daily practice. The 2024 Advanced Prostate Cancer Consensus Conference (APCCC) surveyed experts on key questions in clinical management in order to supplement evidence-based guidelines. Here we present voting results for questions from APCCC 2024. Methods: Before the conference, a panel of 120 international PC experts used a modified Delphi process to develop 183 multiple-choice consensus questions on eight different topics. Before the conference, these questions were administered via a web-based survey to the voting panel members (“panellists”). Key findings and limitations: Consensus was a priori defined as ≥75% agreement, with strong consensus defined as ≥90% agreement. The voting results show varying degrees of consensus, as discussed in this article and detailed in the Supplementary material. These findings do not include a formal literature review or meta-analysis. Conclusions and clinical implications: The voting results can help physicians and patients navigate controversial areas of clinical management for which high-level evidence is scant or conflicting. The findings can also help funders and policymakers in prioritising areas for future research. Diagnostic and treatment decisions should always be individualised on the basis of patient and cancer characteristics, and should incorporate current and emerging clinical evidence, guidelines, and logistic and economic factors. Enrolment in clinical trials is always strongly encouraged. Importantly, APCCC 2024 once again identified important gaps (areas of nonconsensus) that merit evaluation in specifically designed trials.

Original language	English (US)
Pages (from-to)	157-216
Number of pages	60
Journal	European urology
Volume	87
Issue number	2
DOIs	https://doi.org/10.1016/j.eururo.2024.09.017
State	Published - Feb 2025

Funding

We would like to extend special thanks to Dr. A.E. Karon for editorial assistance with the manuscript, which was sponsored by UroToday.com. We thank the APC Society, namely Thomas Cerny and Ruth Lyner, for their support. Ian D. Davis is supported in part by an Australian NHMRC Investigator Grant (2016274). Michael S. Hofman is supported by grants from the Prostate Cancer Foundation, Peter MacCallum Foundation, and an NHMRC Investigator Grant. RE is supported by a National Institute of Health and Care Research grant to the Biomedical Research Centre at the Institute of Cancer Research and Royal Marsden NHS Foundation Trust. We gratefully acknowledge the following organisations for providing financial support for APCCC 2024: The City of Lugano and Movember Foundation, Prostate Cancer Foundation, and ESOF.

Keywords

Adjuvant therapy
Biochemical recurrence
Bone protection
Genetics and genomics
Hormonal treatment
Next-generation imaging
Positron emission tomography
Prostate cancer
Prostate-specific membrane antigen
Salvage therapy

ASJC Scopus subject areas

Urology

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1016/j.eururo.2024.09.017

Cite this

Gillessen, S., Turco, F., Davis, I. D., Efstathiou, J. A., Fizazi, K., James, N. D., Shore, N., Small, E., Smith, M., Sweeney, C. J., Tombal, B., Zilli, T., Agarwal, N., Antonarakis, E. S., Aparicio, A., Armstrong, A. J., Bastos, D. A., Attard, G., Axcrona, K., ... Omlin, A. (2025). Management of Patients with Advanced Prostate Cancer. Report from the 2024 Advanced Prostate Cancer Consensus Conference (APCCC). European urology, 87(2), 157-216. https://doi.org/10.1016/j.eururo.2024.09.017

@article{32ac92de295a44348c3aa88f051c1189,

title = "Management of Patients with Advanced Prostate Cancer. Report from the 2024 Advanced Prostate Cancer Consensus Conference (APCCC)",

abstract = "Background and objective: Innovations have improved outcomes in advanced prostate cancer (PC). Nonetheless, we continue to lack high-level evidence on a variety of topics that greatly impact daily practice. The 2024 Advanced Prostate Cancer Consensus Conference (APCCC) surveyed experts on key questions in clinical management in order to supplement evidence-based guidelines. Here we present voting results for questions from APCCC 2024. Methods: Before the conference, a panel of 120 international PC experts used a modified Delphi process to develop 183 multiple-choice consensus questions on eight different topics. Before the conference, these questions were administered via a web-based survey to the voting panel members (“panellists”). Key findings and limitations: Consensus was a priori defined as ≥75% agreement, with strong consensus defined as ≥90% agreement. The voting results show varying degrees of consensus, as discussed in this article and detailed in the Supplementary material. These findings do not include a formal literature review or meta-analysis. Conclusions and clinical implications: The voting results can help physicians and patients navigate controversial areas of clinical management for which high-level evidence is scant or conflicting. The findings can also help funders and policymakers in prioritising areas for future research. Diagnostic and treatment decisions should always be individualised on the basis of patient and cancer characteristics, and should incorporate current and emerging clinical evidence, guidelines, and logistic and economic factors. Enrolment in clinical trials is always strongly encouraged. Importantly, APCCC 2024 once again identified important gaps (areas of nonconsensus) that merit evaluation in specifically designed trials.",

keywords = "Adjuvant therapy, Biochemical recurrence, Bone protection, Genetics and genomics, Hormonal treatment, Next-generation imaging, Positron emission tomography, Prostate cancer, Prostate-specific membrane antigen, Salvage therapy",

author = "Silke Gillessen and Fabio Turco and Davis, {Ian D.} and Efstathiou, {Jason A.} and Karim Fizazi and James, {Nicholas D.} and Neal Shore and Eric Small and Matthew Smith and Sweeney, {Christopher J.} and Bertrand Tombal and Thomas Zilli and Neeraj Agarwal and Antonarakis, {Emmanuel S.} and Ana Aparicio and Armstrong, {Andrew J.} and Bastos, {Diogo Assed} and Gerhardt Attard and Karol Axcrona and Mouna Ayadi and Himisha Beltran and Anders Bjartell and Pierre Blanchard and Bourlon, {Maria T.} and Alberto Briganti and Muhammad Bulbul and Consuelo Buttigliero and Orazio Caffo and Daniel Castellano and Elena Castro and Cheng, {Heather H.} and Chi, {Kim N.} and Clarke, {Caroline S.} and Noel Clarke and {de Bono}, {Johann S.} and {De Santis}, Maria and Ignacio Duran and Eleni Efstathiou and Ekeke, {Onyeanunam N.} and {El Nahas}, {Tamer I.H.} and Louise Emmett and Stefano Fanti and Fatiregun, {Omolara A.} and Feng, {Felix Y.} and Fong, {Peter C.C.} and Valerie Fonteyne and Nicola Fossati and George, {Daniel J.} and Gleave, {Martin E.} and Gwenaelle Gravis and Susan Halabi and Daniel Heinrich and Ken Herrmann and Hofman, {Michael S.} and Hope, {Thomas A.} and Horvath, {Lisa G.} and Hussain, {Maha H.A.} and Jereczek-Fossa, {Barbara Alicja} and Jones, {Robert J.} and Joshua, {Anthony M.} and Ravindren Kanesvaran and Daniel Keizman and Khauli, {Raja B.} and Gero Kramer and Stacy Loeb and Mahal, {Brandon A.} and Maluf, {Fernando C.} and Joaquin Mateo and David Matheson and Matikainen, {Mika P.} and Ray McDermott and McKay, {Rana R.} and Niven Mehra and Merseburger, {Axel S.} and Morgans, {Alicia K.} and Morris, {Michael J.} and Hind Mrabti and Deborah Mukherji and Murphy, {Declan G.} and Vedang Murthy and Mutambirwa, {Shingai B.A.} and Nguyen, {Paul L.} and Oh, {William K.} and Piet Ost and O'Sullivan, {Joe M.} and Padhani, {Anwar R.} and Chris Parker and Poon, {Darren M.C.} and Pritchard, {Colin C.} and Rabah, {Danny M.} and Dana Rathkopf and Reiter, {Robert E.} and Raphaele Renard-Penna and Ryan, {Charles J.} and Fred Saad and Sade, {Juan Pablo} and Shahneen Sandhu and Sartor, {Oliver A.} and Edward Schaeffer and Scher, {Howard I.} and Nima Sharifi and Skoneczna, {Iwona A.} and Soule, {Howard R.} and Spratt, {Daniel E.} and Sandy Srinivas and Sternberg, {Cora N.} and Hiroyoshi Suzuki and Taplin, {Mary Ellen} and Camilla Thellenberg-Karlsson and Derya Tilki and T{\"u}rkeri, {Levent N.} and Hiroji Uemura and Y{\"u}ksel {\"U}r{\"u}n and Vale, {Claire L.} and Neha Vapiwala and Jochen Walz and Kosj Yamoah and Dingwei Ye and Yu, {Evan Y.} and Almudena Zapatero and Aurelius Omlin",

note = "Publisher Copyright: {\textcopyright} 2024 The Authors",

year = "2025",

month = feb,

doi = "10.1016/j.eururo.2024.09.017",

language = "English (US)",

volume = "87",

pages = "157--216",

journal = "European urology",

issn = "0302-2838",

publisher = "Elsevier B.V.",

number = "2",

}

Gillessen, S, Turco, F, Davis, ID, Efstathiou, JA, Fizazi, K, James, ND, Shore, N, Small, E, Smith, M, Sweeney, CJ, Tombal, B, Zilli, T, Agarwal, N, Antonarakis, ES, Aparicio, A, Armstrong, AJ, Bastos, DA, Attard, G, Axcrona, K, Ayadi, M, Beltran, H, Bjartell, A, Blanchard, P, Bourlon, MT, Briganti, A, Bulbul, M, Buttigliero, C, Caffo, O, Castellano, D, Castro, E, Cheng, HH, Chi, KN, Clarke, CS, Clarke, N, de Bono, JS, De Santis, M, Duran, I, Efstathiou, E, Ekeke, ON, El Nahas, TIH, Emmett, L, Fanti, S, Fatiregun, OA, Feng, FY, Fong, PCC, Fonteyne, V, Fossati, N, George, DJ, Gleave, ME, Gravis, G, Halabi, S, Heinrich, D, Herrmann, K, Hofman, MS, Hope, TA, Horvath, LG, Hussain, MHA, Jereczek-Fossa, BA, Jones, RJ, Joshua, AM, Kanesvaran, R, Keizman, D, Khauli, RB, Kramer, G, Loeb, S, Mahal, BA, Maluf, FC, Mateo, J, Matheson, D, Matikainen, MP, McDermott, R, McKay, RR, Mehra, N, Merseburger, AS, Morgans, AK, Morris, MJ, Mrabti, H, Mukherji, D, Murphy, DG, Murthy, V, Mutambirwa, SBA, Nguyen, PL, Oh, WK, Ost, P, O'Sullivan, JM, Padhani, AR, Parker, C, Poon, DMC, Pritchard, CC, Rabah, DM, Rathkopf, D, Reiter, RE, Renard-Penna, R, Ryan, CJ, Saad, F, Sade, JP, Sandhu, S, Sartor, OA, Schaeffer, E, Scher, HI, Sharifi, N, Skoneczna, IA, Soule, HR, Spratt, DE, Srinivas, S, Sternberg, CN, Suzuki, H, Taplin, ME, Thellenberg-Karlsson, C, Tilki, D, Türkeri, LN, Uemura, H, Ürün, Y, Vale, CL, Vapiwala, N, Walz, J, Yamoah, K, Ye, D, Yu, EY, Zapatero, A & Omlin, A 2025, 'Management of Patients with Advanced Prostate Cancer. Report from the 2024 Advanced Prostate Cancer Consensus Conference (APCCC)', European urology, vol. 87, no. 2, pp. 157-216. https://doi.org/10.1016/j.eururo.2024.09.017

TY - JOUR

T1 - Management of Patients with Advanced Prostate Cancer. Report from the 2024 Advanced Prostate Cancer Consensus Conference (APCCC)

AU - Gillessen, Silke

AU - Turco, Fabio

AU - Davis, Ian D.

AU - Efstathiou, Jason A.

AU - Fizazi, Karim

AU - James, Nicholas D.

AU - Shore, Neal

AU - Small, Eric

AU - Smith, Matthew

AU - Sweeney, Christopher J.

AU - Tombal, Bertrand

AU - Zilli, Thomas

AU - Agarwal, Neeraj

AU - Antonarakis, Emmanuel S.

AU - Aparicio, Ana

AU - Armstrong, Andrew J.

AU - Bastos, Diogo Assed

AU - Attard, Gerhardt

AU - Axcrona, Karol

AU - Ayadi, Mouna

AU - Beltran, Himisha

AU - Bjartell, Anders

AU - Blanchard, Pierre

AU - Bourlon, Maria T.

AU - Briganti, Alberto

AU - Bulbul, Muhammad

AU - Buttigliero, Consuelo

AU - Caffo, Orazio

AU - Castellano, Daniel

AU - Castro, Elena

AU - Cheng, Heather H.

AU - Chi, Kim N.

AU - Clarke, Caroline S.

AU - Clarke, Noel

AU - de Bono, Johann S.

AU - De Santis, Maria

AU - Duran, Ignacio

AU - Efstathiou, Eleni

AU - Ekeke, Onyeanunam N.

AU - El Nahas, Tamer I.H.

AU - Emmett, Louise

AU - Fanti, Stefano

AU - Fatiregun, Omolara A.

AU - Feng, Felix Y.

AU - Fong, Peter C.C.

AU - Fonteyne, Valerie

AU - Fossati, Nicola

AU - George, Daniel J.

AU - Gleave, Martin E.

AU - Gravis, Gwenaelle

AU - Halabi, Susan

AU - Heinrich, Daniel

AU - Herrmann, Ken

AU - Hofman, Michael S.

AU - Hope, Thomas A.

AU - Horvath, Lisa G.

AU - Hussain, Maha H.A.

AU - Jereczek-Fossa, Barbara Alicja

AU - Jones, Robert J.

AU - Joshua, Anthony M.

AU - Kanesvaran, Ravindren

AU - Keizman, Daniel

AU - Khauli, Raja B.

AU - Kramer, Gero

AU - Loeb, Stacy

AU - Mahal, Brandon A.

AU - Maluf, Fernando C.

AU - Mateo, Joaquin

AU - Matheson, David

AU - Matikainen, Mika P.

AU - McDermott, Ray

AU - McKay, Rana R.

AU - Mehra, Niven

AU - Merseburger, Axel S.

AU - Morgans, Alicia K.

AU - Morris, Michael J.

AU - Mrabti, Hind

AU - Mukherji, Deborah

AU - Murphy, Declan G.

AU - Murthy, Vedang

AU - Mutambirwa, Shingai B.A.

AU - Nguyen, Paul L.

AU - Oh, William K.

AU - Ost, Piet

AU - O'Sullivan, Joe M.

AU - Padhani, Anwar R.

AU - Parker, Chris

AU - Poon, Darren M.C.

AU - Pritchard, Colin C.

AU - Rabah, Danny M.

AU - Rathkopf, Dana

AU - Reiter, Robert E.

AU - Renard-Penna, Raphaele

AU - Ryan, Charles J.

AU - Saad, Fred

AU - Sade, Juan Pablo

AU - Sandhu, Shahneen

AU - Sartor, Oliver A.

AU - Schaeffer, Edward

AU - Scher, Howard I.

AU - Sharifi, Nima

AU - Skoneczna, Iwona A.

AU - Soule, Howard R.

AU - Spratt, Daniel E.

AU - Srinivas, Sandy

AU - Sternberg, Cora N.

AU - Suzuki, Hiroyoshi

AU - Taplin, Mary Ellen

AU - Thellenberg-Karlsson, Camilla

AU - Tilki, Derya

AU - Türkeri, Levent N.

AU - Uemura, Hiroji

AU - Ürün, Yüksel

AU - Vale, Claire L.

AU - Vapiwala, Neha

AU - Walz, Jochen

AU - Yamoah, Kosj

AU - Ye, Dingwei

AU - Yu, Evan Y.

AU - Zapatero, Almudena

AU - Omlin, Aurelius

PY - 2025/2

Y1 - 2025/2

N2 - Background and objective: Innovations have improved outcomes in advanced prostate cancer (PC). Nonetheless, we continue to lack high-level evidence on a variety of topics that greatly impact daily practice. The 2024 Advanced Prostate Cancer Consensus Conference (APCCC) surveyed experts on key questions in clinical management in order to supplement evidence-based guidelines. Here we present voting results for questions from APCCC 2024. Methods: Before the conference, a panel of 120 international PC experts used a modified Delphi process to develop 183 multiple-choice consensus questions on eight different topics. Before the conference, these questions were administered via a web-based survey to the voting panel members (“panellists”). Key findings and limitations: Consensus was a priori defined as ≥75% agreement, with strong consensus defined as ≥90% agreement. The voting results show varying degrees of consensus, as discussed in this article and detailed in the Supplementary material. These findings do not include a formal literature review or meta-analysis. Conclusions and clinical implications: The voting results can help physicians and patients navigate controversial areas of clinical management for which high-level evidence is scant or conflicting. The findings can also help funders and policymakers in prioritising areas for future research. Diagnostic and treatment decisions should always be individualised on the basis of patient and cancer characteristics, and should incorporate current and emerging clinical evidence, guidelines, and logistic and economic factors. Enrolment in clinical trials is always strongly encouraged. Importantly, APCCC 2024 once again identified important gaps (areas of nonconsensus) that merit evaluation in specifically designed trials.

AB - Background and objective: Innovations have improved outcomes in advanced prostate cancer (PC). Nonetheless, we continue to lack high-level evidence on a variety of topics that greatly impact daily practice. The 2024 Advanced Prostate Cancer Consensus Conference (APCCC) surveyed experts on key questions in clinical management in order to supplement evidence-based guidelines. Here we present voting results for questions from APCCC 2024. Methods: Before the conference, a panel of 120 international PC experts used a modified Delphi process to develop 183 multiple-choice consensus questions on eight different topics. Before the conference, these questions were administered via a web-based survey to the voting panel members (“panellists”). Key findings and limitations: Consensus was a priori defined as ≥75% agreement, with strong consensus defined as ≥90% agreement. The voting results show varying degrees of consensus, as discussed in this article and detailed in the Supplementary material. These findings do not include a formal literature review or meta-analysis. Conclusions and clinical implications: The voting results can help physicians and patients navigate controversial areas of clinical management for which high-level evidence is scant or conflicting. The findings can also help funders and policymakers in prioritising areas for future research. Diagnostic and treatment decisions should always be individualised on the basis of patient and cancer characteristics, and should incorporate current and emerging clinical evidence, guidelines, and logistic and economic factors. Enrolment in clinical trials is always strongly encouraged. Importantly, APCCC 2024 once again identified important gaps (areas of nonconsensus) that merit evaluation in specifically designed trials.

KW - Adjuvant therapy

KW - Biochemical recurrence

KW - Bone protection

KW - Genetics and genomics

KW - Hormonal treatment

KW - Next-generation imaging

KW - Positron emission tomography

KW - Prostate cancer

KW - Prostate-specific membrane antigen

KW - Salvage therapy

UR - http://www.scopus.com/inward/record.url?scp=85206186686&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85206186686&partnerID=8YFLogxK

U2 - 10.1016/j.eururo.2024.09.017

DO - 10.1016/j.eururo.2024.09.017

M3 - Article

C2 - 39394013

AN - SCOPUS:85206186686

SN - 0302-2838

VL - 87

SP - 157

EP - 216

JO - European urology

JF - European urology

IS - 2

ER -

Management of Patients with Advanced Prostate Cancer. Report from the 2024 Advanced Prostate Cancer Consensus Conference (APCCC)

Abstract

Funding

Keywords

ASJC Scopus subject areas

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this